| Literature DB >> 24900384 |
Sheo B Singh1, Weiguo Liu1, Xiaohua Li1, Tom Chen1, Ali Shafiee1, Deborah Card1, George Abruzzo1, Amy Flattery1, Charles Gill1, John R Thompson1, Mark Rosenbach1, Sarah Dreikorn1, Viktor Hornak1, Maria Meinz1, Myra Kurtz1, Rosemarie Kelly1, Janet C Onishi1.
Abstract
Ilicicolin H is a polyketide-nonribosomal peptide synthase (NRPS)-natural product isolated from Gliocadium roseum, which exhibits potent and broad spectrum antifungal activity, with sub-μg/mL MICs against Candida spp., Aspergillus fumigatus, and Cryptococcus spp. It showed a novel mode of action, potent inhibition (IC50 = 2-3 ng/mL) of the mitochondrial cytochrome bc1 reductase, and over 1000-fold selectivity relative to rat liver cytochrome bc1 reductase. Ilicicolin H exhibited in vivo efficacy in murine models of Candida albicans and Cryptococcus neoformans infections, but efficacy may have been limited by high plasma protein binding. Systematic structural modification of ilicicolin H was undertaken to understand the structural requirement for the antifungal activity. The details of the biological activity of ilicicolin H and structural modification of some of the key parts of the molecule and resulting activity of the derivatives are discussed. These data suggest that the β-keto group is critical for the antifungal activity.Entities:
Keywords: Gliocadium roseum; antifungal activity; broad spectrum; cytochrome bc1 reductase inhibitor; ilicicolin H; in vivo efficacy
Year: 2012 PMID: 24900384 PMCID: PMC4025731 DOI: 10.1021/ml300173e
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345